Survival Analysis in Metastasis Breast Cancer with HER-2 Type That Received Vinorelbine And Capecitabine Chemotherapy at Prof. Dr.I.G.N.G. Ngoerah Central General Hospital
Andersen1*, Putu Anda Tusta Adiputra2, I B Made Suryawisesa2
Abstract
Introduction: Breast cancer remains a leading cause of cancer-related mortality globally, particularly in developing regions. The HER-2 subtype is known for its aggressive nature and poor prognosis. Methods: A retrospective cohort study was conducted involving 42 patients diagnosed with HER-2 positive metastatic breast cancer who received either Vinorelbine or Capecitabine as second-line chemotherapy between January 2015 and December 2021. Survival analysis was performed using Kaplan-Meier curves and Cox regression to assess the impact of chemotherapy type on overall survival (OS) and progression-free survival (PFS). Results: The average OS for patients receiving Vinorelbine was 436.62 days, while those on Capecitabine had an OS of 422.33 days, indicating no statistically significant difference (p=0.874). For PFS, Vinorelbine patients had an average of 280.81 days compared to 308.76 days for Capecitabine, with no significant difference (p=0.725). Discussion: Although both treatments showed similar survival outcomes, Vinorelbine demonstrated a marginally longer OS in this cohort. This suggests that while both agents are viable options, further research is needed to optimize treatment strategies for HER-2 positive metastatic breast cancer patients. Conclusion: The findings emphasize the need for individualized treatment approaches in managing metastatic breast cancer, particularly for HER-2 positive subtypes.
Keywords
HER-2 positive; metastatic breast cancer; Vinorelbine; Capecitabine; survival analysis.
Cite This Article
Andersen., Adiputra, P. A. T., Suryawisesa, I. b. M. (2024). Survival Analysis in Metastasis Breast Cancer with HER-2 Type That Received Vinorelbine And Capecitabine Chemotherapy at Prof. Dr.I.G.N.G. Ngoerah Central General Hospital. International Journal of Scientific Advances (IJSCIA), Volume 5| Issue 6: Nov-Dec 2024, Pages 1205-1217, URL: https://www.ijscia.com/wp-content/uploads/2024/12/Volume5-Issue6-Nov-Dec-No.708-1205-1217.pdf
Volume 5 | Issue 6: Nov – Dec 2024
